Xoma Ltd.’s much-watched experimental diabetes drug failed a key Phase II study, the company said.
XOMA-052 did not hit its primary goal of reducing glycosylated hemoglobin, or HbA1c, compared to a placebo, after six monthly treatments in the Phase IIb trial.
The drug has been discussed as a potential once-a-month treatment for type 2 diabetes that targets inflammation by inhibiting the protein interleukin-1, or IL-1.
No comments:
Post a Comment